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Abstract
The risk of tumorigenicity is a hurdle for regenerative medicine using induced pluripotent stem cells (iPSCs). Although
teratoma formation is readily distinguishable, the malignant transformation of iPSC derivatives has not been clearly
defined due to insufficient analysis of histology and phenotype. In the present study, we evaluated the histology of
neural stem/progenitor cells (NSPCs) generated from integration-free human peripheral blood mononuclear cell
(PBMC)-derived iPSCs (iPSC-NSPCs) following transplantation into central nervous system (CNS) of immunodeficient
mice. We found that transplanted iPSC-NSPCs produced differentiation patterns resembling those in embryonic CNS
development, and that the microenvironment of the final site of migration affected their maturational stage. Genomic
instability of iPSCs correlated with increased proliferation of transplants, although no carcinogenesis was evident. The
histological classifications presented here may provide cues for addressing potential safety issues confronting
regenerative medicine involving iPSCs.
Keywords: Human induced pluripotent stem cells, Regenerative medicine, Cell transplantation, Carcinogenesis,
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Introduction
The transplantation of neural stem progenitor cells
(NSPCs) is considered a promising approach to the treat-
ment of a range of central nervous system (CNS) disor-
ders, including spinal cord injury [1, 2], brain infarction
[3–5], amyotrophic lateral sclerosis (ALS) [6, 7], and
Parkinson’s disease [8]. In countries in which the clinical
use of fetal NSPCs is not permitted due to ethical limita-
tions, induced pluripotent stem cells (iPSCs) represent a
potential alternative source of NSPCs for use in cell
therapy research and development. In Japan, iPSC stocks
[9, 10] are being established from peripheral blood
mononuclear cells (PBMCs) of donors with a range of im-
munologically preferable genotypes. However, before such
cells can be used in clinical applications, the safety of
transplanted cells must be determined.
Transplant safety issues include infection, immuno-
logical problems such as rejection, complications result-
ing from drugs such as immunosuppressants, and
complications resulting from unexpected migration or
transplant behavior [11, 12]. As for stem cells, which
have the potential to develop into a variety of mature
tissue types, efforts must be made to manage the risk of
contamination by undifferentiated pluripotent cells, or
the transformation of graft-derived intermediate progen-
itors into malignant tumor cells [13–16].
Malignant tumors occasionally exhibit immature and
embryonic-like structures, and normal embryonic cells
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share some characteristics with malignant tumor cells;
i.e., normal developing tissues in which stem cell multi-
plication occurs exhibit significant mitotic activity, simi-
lar to that in malignant tumors. Under such conditions,
the cellular mitotic index is not helpful in distinguishing
stem cells from malignant tumors. NSPCs for trans-
plantation therapies also exhibit characteristics of less
developmentally mature cells, and thus it is necessary to
classify the histology of transplanted cells by their devel-
opmental characteristics in order to distinguish them
from the malignant transformation of transplants.
In the present study, we induced NSPCs from
integration-free human peripheral blood mononuclear
cell (PBMC)-derived iPSCs (iPSC-NSPCs) using two
different protocols, compared their in vitro properties,
and also compared their in vivo histology by transplanting
them into intact striata or injured spinal cords of immu-
nodeficient (NOD/Shi-scid, IL-2R γ null (NOG) [17] or
NOD/scid [18]) mice. Our histological categorization may
serve as a useful tool for predicting and describing the
performance of NSPCs for future quality evaluations of
cell products for future transplantation therapy.
Results
Induction of NSPCs from three human PBMC-derived
iPSC lines
Three human integration-free iPSC lines made with epi-
somal vectors (1210B2, 1231A3, and 1201C1) from the
PBMC of single donor were differentiated into NSPCs by
two protocols, which are easily modifiable into xeno-free
protocols for clinical use (Fig. 1a). We refer to NSPCs in-
duced directly from embryoid bodies (EBs) as EB-NSPCs,
and those induced from the neural rosette (NR) phase as
NR-NSPCs. Both EB-NSPCs and NR-NSPCs were ex-
panded as free-floating neurospheres (Fig. 1a).
The differentiation of three iPSC clones into NSPCs
was confirmed with flow cytometric analysis (Fig. 1b and
Additional file 1: Figure S1A) in which low pluripotency
marker expression (TRA-1-60, SSEA4, and CD324 (E-
Cadherin) [19, 20]) and high neural marker expression
(PSA-NCAM) [21] were observed. We also confirmed by
RT-PCR that pluripotency marker expression (POUF5F1
(also called OCT4), NANOG, and LIN28A) decreased,
and neural marker expression (SOX1 and PAX6) in-
creased during their differentiation into NSPCs (Fig. 1c
and Additional file 1: Figure S1B). Statistical analysis did
not reveal any significant differences between EB- and
NR-NSPCs. The differentiation potential of the three
iPSC-derived NSPC clones as classical neural progenitors
was confirmed by induction into neuronal (βIII-tubulin,
ELAVL) and glial (GFAP) lineages by immunocytochem-
istry (Fig. 1d and Additional file 1: Figure S1C). All of the
above assays were performed, and successful neural differ-
entiation was confirmed at passage 6 (EBs) or 7 (NRs) of
the NSPCs, suggesting that all three integration-free hu-
man PBMC-derived iPSCs examined had been induced to
differentiate into NSPCs under both protocols via passage
7. We further characterized and compared the properties
of each induced NSPCs by microarray expression analysis
and found that all EB- and NR-NSPCs from the same
iPSCs had profiles that closely resembled each other, with
correlations of > 97.3 % (Fig. 1e and Additional file 2:
Table S1). These results suggest that the NSPCs we estab-
lished using two independent protocols had similar tran-
scriptome properties. Correlation analyses among the
NSPCs also indicated that 1210B2 iPSCs could be stably
induced into NSPCs with the highest homogeneity; how-
ever, the results of our statistical analysis did not exceed
the significance threshold (Fig. 1e).
Abnormal karyotype and genomic instability in iPSCs result
in altered NSPC proliferative capacities in vitro
To examine the quality of the NSPCs, we evaluated their
proliferation ratios (Fig. 2a). All cells analyzed showed
consistent proliferative properties and could be main-
tained for more than 70 days. Of the cell lines compared,
the NR-NSPCs had a proliferation ratio similar to that of
the EB-NSPCs. Cellular doubling time was faster in the
1231A3 EB-NSPCs and slower in the 1210B2 EB-NSPCs
and 1210B2 NR-NSPCs compared with the other NSPCs
(Fig. 2a). In a cell cycle analysis, 1231A3 NSPCs showed
a lower ratio of cells in the G1/G0 phase, indicating the
presence of a higher population in their proliferative
state (Fig. 2b).
To gain more detailed insights into the different prolifer-
ative kinetics among the NSPCs, we sought to identify any
genetic abnormalities in these cells. In a karyotype analysis,
the 1231A3 NR-NSPCs met the abnormality criterion,
showing a high ratio of gain of chromosome 2 (Fig. 2c and
Additional file 3: Table S2). Furthermore, copy number
variations (CNVs) in NSPCs at passages six and seven were
compared with those of the source iPSCs and NSPCs cul-
tured for an additional five passages. We found that the
largest number of de novo CNVs during differentiation and
neurosphere culture occurred in the 1231A3 NR-NSPCs,
and that CNV frequency increased over the course of add-
itional culture of five passages. No (1210B2 EB-NSPCs) or
single (1210B2 NR-NSPCs) de novo CNV was found in the
1210B2-iPSC-derived NSPCs. A few CNVs were found in
the 1201C1-iPSCs during neural induction; however, the
1201C1-NSPCs were maintained with a stable genome
over 10 passages (Additional file 4: Figure S2, Additional
file 5: Table S3, Additional file 6: Table S4, Additional file
7: Table S5 and Additional file 8: Table S6).
These results suggest that most induced NSPCs can be
safely generated on a large scale for future commercial use;
however, as in the case of 1231A3 NR-NSPCs, NSPCs
may exhibit abnormal karyotypes, resulting in an
Sugai et al. Molecular Brain  (2016) 9:85 Page 2 of 15
Fig. 1 (See legend on next page.)
Sugai et al. Molecular Brain  (2016) 9:85 Page 3 of 15
inhomogeneous, and possibly a highly proliferative
state. Furthermore, many de novo CNVs were found in
NSPCs at passage 6 or 7, and accumulated along with
the culture length in the 1231A3 NSPCs, but very few
de novo CNVs were found in the 1201C1 NSPCs and
1210B2 NSPCs, suggesting that the genomic stability of
the original iPSCs may contribute to genomic instability
of their derivative NSPCs.
Cells with a higher proliferation ratio in vitro formed larger
tissues when transplanted into immunodeficient mice
To further characterize NSPCs in vivo, we trans-
planted them into intact striata of NOG mice or into
post-injured spinal cords of NOD/scid mice (Fig. 3a).
Subsequent histological analyses were performed 12–
26 weeks later by immunostaining with the human
cytosol marker STEM121 [4, 22]. Cell engraftment
patterns were similar to those of NSPCs derived
from iPSCs generated from cells of different somatic
origin (Additional file 9: Figure S3). The extent to
which transplanted cells were distributed differed
among the cell lines evaluated (Fig. 3b c and d). The
1231A3 NSPCs spread over larger areas, and the
1210B2 NSPCs spread over smaller areas, both in
the injured spinal cord and in the brain (Fig. 3b, c
and d). This trend was similar to the results of the
in vitro proliferation analysis, suggesting that the
cellular proliferation characteristics were maintained
even after transplantation into mice.
Terminal histology of transplanted NSPCs mimic a fetal
neural differentiation pattern
Following the characterization of NPSC proliferative
capacities in vitro and in vivo, it remained unclear how
iPSC-derived NSPCs differentiate, distribute, and con-
tribute to host tissue. Assessment of the tumorigenicity
of iPSC-NSPCs-derivatives is also an important goal. To
clarify and classify the histology of the transplants in de-
velopmental terms, we also transplanted other NSPC
lines [20, 23, 24] and performed histochemical analysis
(Table 1 and Figs. 4 and 5). For a comparator, we used
long-term self-renewing neuroepithelial-like stem cells
(lt-NESCs) [20, 24, 25] to determine whether cells culti-
vated in an adhesive culture in vitro behave differently
in vivo. Additionally, we also used fetal-derived NS/PCs
[23] as a control that does not malignantly transform,
based on previous observations. As a result, although
the transplanted iPSC-derived NSPCs and fetal-derived
NSPCs mainly differentiated into neural and rarely mes-
enchymal tissues, tissue maturity was closely associated
with the sites to which transplanted cells terminally mi-
grated (Table 1A, B).
When graft-derived cells were found in the vicinity of
the central canal or the pia mater, they often formed
neural differentiated tissues, which were further classifi-
able into two groups according to their maturation level
(Table 1A and Figs. 4A, B and 5a, c, d): (1) a well-
maturing/matured group, termed differentiating neural
tissue (DNT), and (2) an under-matured group, which
we termed undifferentiated neural tissue (UDNT), and
blastemal tissue (BLT). Scattered transplanted cells that
reached neither the central canal nor the pia mater were
defined as migrating neural cells, which were also classi-
fiable into immature/maturing and mature subtypes
(Table 1B and Fig. 5b).
The tissue pattern, which we named DNT, typically
consisted of three different maturational stages of neural
tissue that showed sequential differentiation that closely
resembled zone formation in fetal spinal cord or brain
development (Fig. 5a). More specifically, cells that were
only Nestin-positive appeared to migrate into the epen-
dymal cell layer beneath the central canal or into the pia
mater where it was considered equivalent to the ven-
tricular zone (VZ). Of these cells, neuroepithelium-like
or subependymal cell-like neural stem cells differentiated
into glial and neuronal lineages and formed an area his-
tologically similar to the intermediate zone (IZ) (Figs. 4A,
B and 5a). The IZ-equivalent area subsequently transited
to a cell-poor area that consisted mostly of fibers distal
from the VZ zone, which we considered equivalent to
the marginal zone (MZ) (Figs. 4A, B and 5a). In some
cases, the DNT was not identifiable by H&E staining, as
it intermingled well with the pre-existing host nerve
tissue, which supported its successful maturation. Add-
itionally, the DNT could be further classed into two
subtypes based on the terminal destinations of the trans-
planted stem cells: a parenchymal (conventional) sub-
type, which arose from subependymal areas of the
(See figure on previous page.)
Fig. 1 Schematic neural induction diagrams and characterization of the NSPCs generated from human PBMC-derived iPSCs. a Schematics of the
NSPC induction protocols used in this study. (Scale = 200 μm for the images of neurospheres.) (b, c, d) Representative data taken by 1210B2-NSPCs for
characterization analysis of the NSPCs. b Cell surface markers of the induced NSPCs. c The quantitative RT-PCR analysis results are depicted by ΔCt
values. Quantitative RT− PCR analysis confirmed the decrease in the iPSC markers, and an increase in NSPC markers following the differentiation of
iPSCs into NSPCs. (n = 2 for each iPSC-NSPC lines) d Representative immunocytochemistry data collected to confirm the differentiation potential
of NSPCs into neuronal and glial lineages. (Scale = 100 μm.) e The correlation coefficients of the expression profiles among the NSPCs. The microarray
profiles were similar between all the NSPCs regardless of the induction protocols or iPSCs. (n = 2 for each iPSC-NSPC lines) See also Additional file 1:
Figure S1 and Additional file 2: Table S1
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Fig. 2 In vitro abnormality analysis of the induced NSPCs. Karyotype abnormalities were seen in the 1231A3 NSPCs and CNV abnormalities were
seen in the 1231A3 and 1201C1 NSPCs. a Cellular doubling times were calculated by measuring ATP consumption for each of the NSPC lines. b
The cell cycle for each NSPC cell line. Although a higher percentage of 1231A3-NSPCs were in S phase, there was no significant difference between
the cell lines. c Results of karyotype analysis by G band-staining are shown. Only the 1231A3 NR-NSPCs had a karyotype abnormality. See also
Additional file 4: Figure S2, and Additional file 5: Tables S3, Additional file 6: Table S4, Additional file 7: Table S5 and Additional file 8: Table S6
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central canal, and a subpial subtype, derived from cells
that attached to the pia mater.
The tissue patterns, which were referred to as undiffer-
entiated neural tissue (UDNT) and blastemal tissue
(BLT), were under-matured and exhibited incomplete
and arrested differentiation of nervous tissues, respect-
ively, which were frequently found outside the spinal
cord or brain parenchyma (Fig. 4A, B). The UDNT was
typically composed of incompletely differentiated neural
cells within a myxomatous background and were
Fig. 3 Histology revealed proliferative characteristics of the 1231A3-NSPCs both in intact brains and injured spinal cords. a Schematic of the in
vivo transplantation protocol that was used. b Representative tissue sections of the spinal cord (upper row, 12 weeks after transplant) and brain
(lower row, 26 weeks after transplant) after the transplantation of each cell line. Immunohistochemistry results for STEM121 and DAB, which were
positive in the cytoplasm of the transplanted human cells. (Scale = 500 μm.) (c, d) The mean graft volume percentages in the injured spinal cord
(c) and brain (d) sections are shown. Although the volumes were generally smaller in the brains compared with the injured spinal cords, the
1231A3 EB-NSPCs showed significantly greater proliferation levels in both the spinal cord and brain, and the 1231A3 NR-NSPCs also formed large
tissues. Values are means ± SEM. *P < 0.05 (c: n = 4, 4, 4, 6, 3, 3. d n = 2, 3, 6, 6, 6, 6)
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characterized by Nestin expression and the absence or
faint expression of GFAP (Fig. 5c). The UDNT was
thought to originate from blastemal cells and to be able
to partially differentiate into mature neural cells. BLTs
were observed as an aggregation of cells with an embry-
onic appearance with or without neural processes; these
cells positively or negatively expressed Nestin, indicating
remnants of the primitive neural cells (Fig. 5d). BLT in
the meninges tended to extend in a rostro-caudal direc-
tion. We observed that BLT is able to differentiate into
UDNT, as transition foci from blastemal cells to UDNT
were occasionally found. We also confirmed BLT matur-
ational capacity by comparing the spinal cord histology
at weeks 12 and 26 post-human-fetal NSPC transplant
(Additional file 10: Figure S4A, S4B). Interestingly, the
BLT in the meninges rarely differentiated into benign
mesenchymal tissues (Additional file 10: Figure S4C).
These mesenchymal tissues may be the result of con-
tamination by cells from other lineages, such as
neural crest stem cells (NCSCs), indicating that BLT
histology possibly includes cells of both neural and
mesenchymal lineages.
Among the animals analyzed, no mice developed malig-
nant tumors or teratomas derived from the transplanted
cells. Furthermore, no mice that received transplants to
injured spinal cord showed evident paralysis from the pro-
liferation of the transplants, as observed in a previous re-
port [14]. There was a tendency for spinal cord-injured
mice to show weakness in the lower limbs after 5 months;
however, this may reflect a more general tendency of the
mice used, as not all of them with weakness had large tis-
sue formations from the transplants, and the life
expectancy of NOD/scid mice is estimated at ~8 months
(Additional file 11: Figure S5A, S5B).
After comparing the in vitro data with the in vivo
histological classifications of the six NSPC lines pro-
duced for this study (Table 2), the 1231A3 EB-
NSPCs with the CNV abnormalities tended to re-
main in an immature state. However, the 1231A3
NR-NSPCs, which had larger CNV abnormalities and
also karyotype abnormalities, or the 1201C1 NSPCs,
which also had some CNV abnormalities, did not
show apparent immature phenotypes. These results
indicate that the cellular CNV or karyotype-only ab-
normalities do not explain the maturation arrest of the
transplants in vivo. Rather, transplant maturation was af-
fected by the terminal destination tissue to which trans-
planted cells migrated.
Public registry of histology data and histological
diagnoses from this study
To share the large amount of information from our
histological sections and the histological diagnoses per-
formed in this study, we registered a set of our organized
data to an open-access website (https://www.skip.med.
keio.ac.jp/iPSC-NSPC/). High-resolution images of every
histological section of the 137 mice used in this study
that are not shown in this paper are accessible on this
website, which makes it possible to scan across and mag-
nify individual sections of large images. This online arch-
ive also contains the precise histological definitions and
diagnoses for each section, which we hope will contribute
to further discussion of histological derivatives following
Table 1 Classification of the tissue histology formed by iPSC-NSPCs in mouse CNS
(A) Histology classification of tissues with maturational patterns.
Differentiation Neural differentiation Mesenchymal differentiation
Maturation Maturing/matured Under-maturation Maturing/matured
Histology (Identification on
H&E staining)
DNT (either identifiable or non-
identifiable)





around central canal or cyst
(2)Subpial DNT;
beneath the pia matter




UDNT: Extraparenchymal and intraparenchymal
(B) Scattered neural cell classification.
Migrating neural cells Subpial neural cells
Maturation Immature/maturing (NESTIN+/-) Immature/maturing (NESTIN+/-)
Mature (NESTIN-)
Fate (1) Individual cell maturation Contribute to subpial DNT formation
(2) Contribute to DNT formation
(3) Possibly involved in UDNT
formation
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Fig. 4 NSPC histology schematic in injured spinal cord and brain, according to the maturational pattern. A, B The transplant fate schematics in an injured
spinal cord (A) and an intact brain (B). The transplanted cells reached the edge of a cyst that resembled the central canal in the injured spinal cords (a), the
ventricle of brain (a’), the inner pia mater (b, b’), or vessels in the brain striatum (c’), which recapitulated fetal central nervous system development consisting of
DNT. Medullary DNT arose from the edge of the central canal where transplanted cells transformed into neuroepithelium and neuroblasts (closed diamond),
which gave rise to three cellular zones with different maturation patterns (ventricular zone (VZ)-, intermediate zone (IZ)-, and marginal zone (MZ)-like structures),
as observed in fetal brain development. The migrating neural cells attached to the inner pia mater become flattened in shape (subpial neural cells, closed
square), which had an equivalent immunophenotype to a VZ component of the DNT. UDNTarecomposedof cells that showaVZequivalent immunophenotype,
whichare thought tobe formedas theconsequenceof amaturational delay in theDNT formationprocess (brokenarrows).cThemigrating transplantedcells thatdid
not reach theaboveneurogenesis initiation sitesmaydifferentiate intomatureneural cells (scatteredneural cells: SNC, indicatedbya star) or fail todifferentiate andmay
formaUDNT (brokenarrow). SNCsmight alsobederived fromDNT.d,d’The transplantedcells that failed toengraft into theparenchymaexhibit arrestedor incomplete
neural differentiation (BLT,UDNT)ormesenchymaldifferentiation (MES)
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Fig. 5 Representative images of DNT, UDNT, and BLT. a, b Representative images of the DNT with zone formation around the central canal resembling
cysts, which were observed in the 1231A3 NR-NSPC transplanted spinal cords 6 months after transplantation. a The red arrows indicate the cyst, blue
arrows indicate the VZ, and black arrows indicate the IZ. Upper panel: H&E, STEM121, hNestin, and hGFAP. (Scale = 500 μm.) Lower panel: STEM121,
hNestin, and hGFAP. (Captured in boxed area 1 in the first panel. Scale = 100 μm.) (b) STEM121+ scattered neural cells (SNCs) observed in the MZ that
formed in the rostral end of boxed area 2 in Fig. 5A are indicated by white arrows. There were many more migrating neural cells than is indicated.
(Scale = 50 μm.) (c) Representative histologic features of the UDNT, as observed in a 1201C1 EB-NSPCs transplanted spinal cord at the 12th week after
transplantation. Upper panel: STEM121 and H&E. (Scale = 500 μm.) Lower panel: H&E, hNestin, hGFAP, hKi67, Alcian Blue, and HNA. (Captured in the
boxed area in the upper panel. Scale = 50 μm.) (d) Representative histologic features of the BLT as observed in a 1210B2 NR-NSPC transplanted spinal
cord at the 12th week after transplantation. The low power field views of the STEM121 staining is the same image in Fig. 3b. Upper panel: STEM121 and
H&E. (Scale = 500 μm.) Lower panel: H&E, hNestin, hGFAP, and hKi67. (Captured in the boxed area in the upper panel. Scale = 50 μm.)
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NSPC transplantation, as well as safety issues and possibil-
ities for clinical applications.
Discussion
The risk of teratoma formation by transplanted iPSC-
derivatives is widely recognized, and many attempts have
been made to minimize such risks [26, 27]. Although the
transformation of iPSC-derived products has not been
studied as extensively, a number of reports have showed
the transformation of iPSC-derived intermediate progeni-
tor cells as the result of genetic modification [14, 28, 29],
transgene activation [30], or epigenetic events [31]. We
used integration-free iPSCs to minimize the risk of genetic
modification and/or transgene re-activation, which were
observed in a previous report by our group [14]. However,
some of the NSPCs from the three integration-free iPSCs
used in this study retained proliferative characteristics in
vitro and in vivo, which appeared to be attributable to
karyotype abnormalities or de novo CNVs that occurred
during differentiation and culture processes. As the three
iPSC-lines utilized in the present study were induced from
blood samples from a single donor, the different genomic
abnormalities observed in our iPSC lines may have oc-
curred either during the reprogramming process or in cell
culture. This suggests that even when integration-free
iPSCs are used, it is not possible to completely eliminate
the risk of genetic instability during NSPC production.
This also indicates that the neural induction protocols that
we used cannot eliminate all cells with genetic instability,
and that genetic differences that emerged during the re-
programming process from the original iPSCs cannot be
fully standardized. To control the proliferation of the de-
rivatives in vivo, we thus should use iPSC lines without
karyotype abnormalities or genomic instabilities.
Table 2 Comparison of histological classifications and the abnormalities observed in the in vitro analysis of each iPSC-NSPC line





3 months/ 6 months)
Percentage of neural differentiation seen in each experiment
(histology taken at 3 months/6 months)
Spinal cord Graft failure DNT UDNT BLT
Brain
1210B2 EB-NSPCs CNV (no de novo, very
few additional)
3/2 None 100 %/100 % 33 %/0 % 33 %/0 %
(n = 3/2) (n = 1/0) (n = 1/0)
3/2 None 100 %/100 % None None
(n = 3/2)
1210B2 NR-NSPCs CNV (one de novo, very
few additional)
3/2 33 %/0 % 0 %/ 100 % 33 %/0 % 67 %/0 %
(n = 1/0) (n = 0/2) (n = 1/0) (n = 2/0)
3/2 None 100 %/100 % None None
(n = 3/2)
1231A3 EB-NSPCs CNV (many de novo, some
additional)
2/3 0 %/33 % 100 %/67 % 100 %/67 % 0 %/33 %
(n = 0/1) (n = 2/2) (n = 2/2) (n = 0/1)
3/3 None 100 %/100 % 67 %/100 % None
(n = 3/3) (n = 2/3)
1231A3 NR-NSPCs Karyotype
CNV (many de novo, many
additional)
3/3 None 67 %/100 % 33 %/0 % 33 %/0 %
(n = 2/3) (n = 1/0) (n = 1/0)
3/3 None 100 %/100 % None None
(n = 3/3)
1201C1 EB-NSPCs CNV (some de novo, no
additional)
3/0 None 100 % /- 33.3 %/- None
(n = 3/-) (n = 1/-)
3/3 None 100 %/100 % 0 %/67 % None
(n = 3/3) (n = 0/2)
1201C1 NR-NSPCs CNV (some de novo, no
additional)
3/3 33 %/67 % 67 %/33 % 33 %/0 % None
(n = 1/2) (n = 2/1) (n = 1/0)
5/1 None 100 % /100 % None None
(n = 5/1)
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Culture duration is also important in controlling the
genomic and epigenomic character of cultured cells.
Young iPSCs may be immature and unstable, but it has
also been reported that culture-induced genomic and
epigenomic aberrations can occur at any stage, as the
undifferentiated state of iPSCs is inherently unstable and
sensitive [32]. We decided to use iPSCs as early as 11
passages for neural induction from feeder-free cultured
iPSCs (1210B2 and 1231A3), in order to lower the risk
of genetic abnormality associated with long-term culture
process. Induced pluripotent stem cells established using
the same method have been reported to express
pluripotency-markers by passage 5 [33]. We also con-
firmed expression of pluripotent markers in our cells by
passage 11. Additionally, we needed to cultivate the cells
for this length to obtain a sufficient number of cells for
further use. With respect to on-feeder iPSCs (1201C1),
we needed to culture these until passage 19 in order to
obtain sufficient numbers of cells. The adequate passage
numbers of iPSCs or NSPCs may thus differ depend-
ing on the culture method and the purpose of usage
of cells, a condition that should be evaluated for each
case.
It has been reported that iPSCs tend to acquire epi-
genetic and genetic modifications, including CNVs, dur-
ing the reprogramming process and subsequent cell
culture [34–36], and that these genetic alterations may
occur in genomic sites related to cancer development. It
is impossible to eliminate the risk of genetic abnormal-
ity; however, our results with the 1210B2 EB- and NR-
NSPCs indicate that the proliferative capacity of the
NSPCs can be lowered by selecting cells with few gen-
etic abnormalities. Careful assessment of cells, including
their genomic stability, may thus be useful for reducing
risks in transplantation.
Considering the differentiation of the induced NSPCs
in vivo, the differentiation tendency was affected by the
induction protocols used. It has also been reported that
cellular migration or survival is affected by the injection
site, timing of the transplant after injury, as well as by
transplant dose [37–39]. These properties are relevant to
the normal mammalian CNS developmental process.
During mammalian CNS development, NSPCs gain tem-
poral and positional identities, and thus acquire defined
and limited plasticity, such as neurons or glial cells
[40, 41]. We categorized the maturation of trans-
planted NSPCs by their formation of different devel-
opmental tissues, and found that the environment of
the cells’ terminal destination site affected their devel-
opmental fate. When transplanted cells engrafted out-
side the CNS parenchyma, they nearly always
underwent maturational arrest or delay of neural tis-
sues, which were represented by BLT and UDNT. BLTs
are the most primitive tissues, and when they were
rarely found within the parenchyma, they exhibited ex-
tensive neural differentiation and maturation character-
istics (Additional file 9: Figure S3A, S3B). In support of
these developmental events, transplanted cells within
the parenchyma of the CNS often formed neural tissues
with adequate maturation (DNT).
These results indicate that the control of cellular mi-
gration is useful in controlling the fate of transplants.
Considering the potential for clinical application of
NSPC transplantation, the preferable histology would be
different according to each purpose. Animal models with
environments similar to those of recipient patients will
be most informative with respect to the engraftment
style and the migration potential of the NSPCs. How-
ever, in addition to NSPC transplantation using animal
models that precisely reflect the disease environment in
clinical settings, other conventional animal models may
be used for specific purposes. For example, when asses-
sing NSPCs to be used in the development of SCI treat-
ments, we should select animal models of spinal cord
injury to evaluate cellular maturation stages. Transplant-
ation into intact animal brain, which is much easier and
enables the assessment of larger numbers of cells at a
given time, would also be informative in the assessment
of the proliferative capacity of transplanted cells, as the
proliferative tendencies of each cell line were similar in
the intact brains and injured spinal cords evaluated in
our study.
Interestingly, it appeared that neural tissues were
regularly generated in developmental stages from par-
ticular regions (e.g., central canal, central canal-like
cyst, and pia mater), particularly in injured spinal cords,
whereas they frequently formed and grew in a round
shape without associations with ventricles in non-
pathologic brains. Other studies also indicate that cells
proliferate better under pathologic conditions [38, 42].
We speculate that under pathologic conditions, trans-
planted cells may favor migration into appropriate areas
from which tissue or organ regeneration can be initi-
ated, as is observed in fetal development, thus resulting
in better engraftment.
The aim of the present study was to classify the hist-
ology of transplanted human iPSC-NSPCs in the mouse
CNS by developmental potential to aid in the identifica-
tion of malignant transformations of transplants during
safety assessment of cells intended for use in transplant-
ation therapy. Distinguishing between embryonic tissues
and tumors by microscopy is difficult, as normal devel-
oping tissues in which stem cell multiplication occurs
have significant mitotic activity similar to that of malig-
nant tumors. Furthermore, in humans, especially in chil-
dren, it is known that tumors often arise from remnants
of embryonal tissues; however, the majority of such tis-
sues involute or differentiate into mature tissues [43].
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The definition of a tumor is a mass of cells that prolif-
erate without relation to pattern or rate of the growth of
the part in which it is located. This unlimited cellular
growth may lead to the development of malignant prop-
erties, including invasion of surrounding tissues and me-
tastasis to other organs [44]. In this study, we concluded
from the following observations that none of the trans-
planted cells developed into malignant tumors. 1) We
observed that the transplanted cells generated nervous
tissues with differentiation regularity and limited growth,
which we interpreted as a recapitulation of zonal forma-
tion in CNS development, as represented by characteris-
tic DNT features. 2) Some UDNTs showed extensive
growth along the meninges. This may suggest that these
cells have unlimited proliferation potential and imma-
ture properties. However, the margin of this tissue was
smooth and tended toward neural maturation, and no
invasion of adjacent tissues has been observed so far.
We thus classed this histologic subtype as tissue over-
growth accompanying cellular immaturity. 3) BLT in-
duces the emergence of embryonal tumors, such as
neuroblastomas, medulloblastomas, primitive neuroecto-
dermal tumors, and Wilms tumors. The BLTs observed
in the current study were a confined tissue that was oc-
casionally found in the meninges. Additionally, BLT
lacks mitotic figures and can differentiate into neural
and mesenchymal lineages. These features may more
closely resemble perilobar nephrogenic rests (PLNR),
which are embryonal tissue remnants observed in kid-
neys of patients with overgrowth syndrome [45]. BLT
may differentiate into mature tissue or regress, as is ob-
served in PLNRs. Only a few PLNR types develop into
Wilms tumors [46].
Considering the implications for these observations
in human, we predict that if transplanted iPSC-
derived cells can become cancer cells, they would be
BLT-derived embryonal tumor cells that tend to
localize in the meninges rather than an adult cancer
type. We did not observe any cancerous lesions in
the present study, but recognize that any cell has the
potential to develop into cancer. Longer-term obser-
vation is thus required to determine ways in which
malignant tumorigenesis can be inhibited.
Several approaches to the minimization of transplant-
ation risk have been reported. In addition to eliminating
pluripotent cell contamination, controlling the prolifera-
tive characteristics of cells by pre-treating them with
MitomycinC [47] or γ-secretase [48] may be effective.
Transplant ablation by transgenic HSV-tk and gancyclo-
vir administration [49], or a caspase-based artificial cell
death switch (iCaspase-9) [50] may also be effective in
cases of malignancy. In all cases, the correct diagnosis of
acceptable or unacceptable histology must be made.
From this perspective, our histological classification is
also an effective approach for optimizing the safety of
NSPC transplants.
These results provide important histological insights
into the transplantation of human NSPCs into the CNS
of animal models, with a focus on safety issues confront-
ing future cell transplant therapeutics.
Methods
Additional details regarding several of the protocols used
in this work are provided in the Additional files 12, 13,
14 and 15: Supplemental Experimental Procedure and
Tables S7-S9.
Cell culture
Three lines of integration free human PBMC-derived
iPSCs (1210B2, 1231A3, and 1201C1), which were estab-
lished from ePBMCs® from the Cellular Technology
Limited (OH, USA) at Center for iPS Cell Research and
Application (CiRA: Kyoto, Japan) by an integration-free
method [51], were used. The 1210B2 and 1231A3 iPSCs
were cultured with a feeder-free protocol [33], and the
1201C1 iPSCs were cultured with an on-feeder protocol
that uses SNL feeder cells. They were induced into
NSPCs as previously described [52, 53] with two slight
modifications. Briefly, in the first protocol, the NSPCs
were induced directly from embryoid bodies (EBs) by a
protocol that consists only of a floating culture. In the
second protocol, the EBs were adhered to laminin-
coated culture dishes on day 7, and they subsequently
formed neural rosettes (NRs), which were picked on day
14. We refer to NSPCs induced directly from EBs as
EB-NSPCs, and those induced from the NR phase as
NR-NSPCs. The NSPCs were expanded using the
neurosphere culture technique [23, 54].
Cellular analysis
Detailed experimental procedures were described in the
supplemental materials. For the microarray analysis,
total RNA was analyzed using Human Genome U133
Plus 2.0 Arrays (Affymetrix Inc., Santa Clara, CA) ac-
cording to the manufacturer’s instructions. RT-PCR ana-
lysis was performed, as described previously [54]. Cell
surface marker expression was analyzed with a BD FACS
Verse (BD Biosciences, San Jose, CA). For cell cycle ana-
lysis, the DNA contents of the cells were analyzed by
propidium iodide staining with an EC800 Analyzer (Sony
Biotechnology Inc., Tokyo, Japan). The proliferation assay
was performed by measuring ATP with a CellTiter-Glo
Luminescent Cell Viability Assay (Promega, Madison, WI)
on an ARVO X5 Multilabel Plate Reader (PerkinElmer,
Waltham, MA). The cellular doubling time was calculated
from the intensities of two sampling points in the logarith-
mic growth phase, as previously shown [23]. The karyo-
type analysis was performed by conventional Giemsa
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staining and G-band analysis, and diagnosed as issued in
the 2013 international system for human cytogenetic no-
menclature (ISCN 2013) [55]. CNV was analyzed using a
CytoScan HD Array (Affymetrix Inc., Santa Clara, CA)
according to the manufacturer’s instructions. For NSPC
differentiation, cells were plated on Matrigel (Corning)
and cultured in the same medium, supplemented with 1 %
fetal bovine serum instead of growth factors. Phenotype
analysis of differentiated cells was performed using im-
munocytochemistry on an IX81 microscopy with a fluor-
escence module (Olympus Corp., Tokyo Japan).
Animal model and cellular transplantation
All mouse studies were conducted in strict accordance
with the Guide for Care and Use of Laboratory Animals
of the Central Institute for Experimental Animals (CIEA,
Kanagawa, Japan), and the experimental protocols were
approved by the CIEA Animal Care Committee (Permit
Number: 11029A) in accordance with Keio University
School of Medicine (Tokyo, Japan) (Permit Number:
16-096-25).
For the brain transplant model, NSPCs were injected
bilaterally into the striata of 9 week-old female NOG
mice (2.0×106 cells per mouse) (Clea Japan, Tokyo,
Japan). For the spinal cord injury models, the cell trans-
plantations were performed on 9 week-old female NOD/
scid mice (Charles River Laboratories Japan, Inc., Tokyo,
Japan), as previously described [14]. Briefly, 5×105
NSPCs were transplanted to the epicenter of the injury
9 days after the moderate contusion injury (IH impactor,
60-70kdyn). After the transplantation, the brain trans-
plant models were monitored for abnormal behavior,
and the spinal cord injury models were monitored for
lower limb motor function using the Basso Mouse Scale
(BMS) [56].
The mouse strain type differed between the transplant-
ation models because of the capacity lamination of our
facility to harvest immunodeficient animals.
Histological Analysis
Twelve to 26 weeks after transplantation, mice were sacri-
ficed, and their brains or spinal cords were taken to make
paraffin sections, which were evaluated via H&E staining
or immunohistochemistry. In all the sagittal spinal cord
sections, the left side indicates the rostral and the upper
side indicates the dorsal side of the section.
The extent of the transplants in the CNS of the trans-
planted animals was analyzed by measuring the STEM121-
positive and -negative areas using Adobe Photoshop
(version 13.0; San Jose, CA, USA).
To produce pathological classifications, additional hist-
ology data from transplantation of human fetal NSPCs
and other iPSC-derived NSPCs were evaluated.
Statistics
A significance criterion of p < 0.05 was used. A nonpara-
metric Kruskal-Wallis test followed by the Mann-Whitney
U test were used to analyze RT-PCR and graft volumes.
Additional files
Additional file 1: Figure S1. Supplemental 1231A2-NSPC and 1201C1-
NSPC data for Fig. 1b, c, and d. (A) FACS analysis results. (B) RT-PCR analysis
results. (C) In vitro differentiation assay immunocytochemical data results.
(Scale = 100 μm.). (TIF 3241 kb)
Additional file 2: Table S1. Gene expression profile correlation
coefficients. (XLSX 46 kb)
Additional file 3: Table S2. Karyotype analysis results of NSPCs using
conventional giemsa staining and G-banding. (XLSX 43 kb)
Additional file 4: Figure S2. Supplemental CNV analysis data. Complete
CNV data for the performed whole genome view. (TIF 2632 kb)
Additional file 5: Table S3. Summary of the in vitro de novo copy
number variations (CNVs) in the NSPCs. (A) Total numbers of the de novo
CNVs in NSPCs during neural differentiation and neurosphere culture by
passage 7. (B) Numbers of the CNVs in NSPCs additionally identified after
additional 5 passages of neurosphere culture. (XLSX 36 kb)
Additional file 6: Table S4. De novo copy number variations (CNVs)
identified in the 1210B2 iPSC-derived NSPCs. (XLSX 39 kb)
Additional file 7: Table S5. De novo copy number variations (CNVs)
identified in the 1231A3 iPSC-derived NSPCs. (XLSX 79 kb)
Additional file 8: Table S6. De novo copy number variations (CNVs)
identified in the 1201C1 iPSC-derived NSPCs. (XLSX 35 kb)
Additional file 9: Figure S3. Representative tissue sections of the spinal
cord (upper row, 12 weeks after transplant) and brain (lower row, 12 weeks
after transplant) after the transplantation of AF22. Immunohistochemistry
results for STEM121 and DAB, which were positive in the cytoplasm of the
transplanted human cells. (Scale = 500 μm.). (TIF 2126 kb)
Additional file 10: Figure S4. Representative images of transplant-
derived tissue from human embryo-derived NSPCs and NSPCs with
portions of NCSCs. (A) An injured spinal cord 12 weeks after transplantation
with human embryo-derived NSPCs. The red arrow indicates the hGFAP
negative BLT. Upper panel: H&E and STEM121. (Scale = 500 μm.) Lower
panel: H&E, hNestin, hGFAP, and Ki67. (Captured in the boxed area in the
upper panel. Scale = 100 μm.) (B) An injured spinal cord 26 weeks after
transplantation with the same NSPCs used in Additional file 9: Figure S3A.
Most of the blastemal features of the transplants observed at week
12 disappeared by week 26, which shows the maturational capacity
of the BLT. Upper panel: H&E and STEM121. (Scale = 500 μm.) Lower
panel: H&E, STEM121, and hGFAP. (Captured in the boxed area in the
first panel. Scale = 100 μm.) (C) Representative histology of mesenchymal
tumors derived from 1210B2-ltNESC. Here, the transplanted NSPCs had
some NCSC contamination. The section evaluated 26 weeks after
transplantation revealed transplant-derived bone formation in the
meningeal space. Upper panel: H&E. (Scale = 500 μm.) Lower panel:
H&E and STEM121 (Captured in the boxed area in the first panel.
Scale = 100 μm.). (TIF 7362 kb)
Additional file 11: Figure S5. Open field scores for mice with
transplantations in their injured spinal cords. (A) Every mouse with a
spinal cord injury was evaluated for lower limb motor function. The red
lines indicate mice with histology shown in Fig. 3b. *A mouse that had
its histology used in Fig. 5a. **Mice with weakness at the end of the
observation period. (B) STEM121 immunostaining of their spinal cords at
week 26 shows that the weakness did not always accompany a large
lesion that was occupied by the transplants. (TIF 4013 kb)
Additional file 12: Supplemental experimental procedures. (DOCX 25 kb)
Additional file 13: Table S7. Primer information (XLSX 35 kb)
Additional file 14: Table S8. Antibodies utilized for flow cytometry
(XLSX 37 kb)
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Additional file 15: Table S9. Antibodies utilized for immunostaining
(XLSX 43 kb)
Abbreviations
BLT: Blastemal tissue; CNS: Central nervous system; CNVs: Copy number
variations; DNT: Differentiating neural tissue; EB: Embryoid body; iPSC: induced
pluripotent stem cell; IZ: Intermediate zone; lt-NESCs: Long-term self-renewing
neuroepithelial-like stem cells; MZ: Marginal zone; NCSCs: Neural crest stem cells;
NR: Neural rosette; NSPC: Neural stem progenitor cell; PBMC: Peripheral blood
mononuclear cell; UDNT: Undifferentiated neural tissue; VZ: Ventricular zone;
Acknowledgements
We thank Center for iPS Cell Research and Application (CiRA: Kyoto, Japan)
for kindly providing the PBMC-iPSCs. We are also very grateful to the members
of the spinal cord research team at the Department of Orthopaedic Surgery,
Rehabilitation Medicine and Physiology and the members of the Department
of Physiology, Keio University School of Medicine, as well as the members of
the Institute for Clinical Research, Osaka National Hospital for their valuable
assistance with the in vitro and in vivo experiments and animal care. We also
thank Dr. Tohru Masui, Dr. Kenjiro Kosaki, and members of the SKIP Operating
Committee for their assistance with making our database on the SKIP website,
and also to Prof. Douglass Sipp (Keio University) for his invaluable comments
on the manuscript.
Funding
This work was supported in part by grants from the Japan Science and
Technology (JST)–California Institute for Regenerative Medicine (CIRM)
Collaborative Program; Grants-in-Aid for Scientific Research from the Japan
Society for the Promotion of Science (SPS) and the Ministry of Education,
Culture, Sports, Science and Technology of Japan (MEXT); and a grant from
the Research Center Network for Realization of Regenerative Medicine from
JST and Japan Agency for Medical Research and Development (AMED) (to
H.O., M.N. and Y.K.).
We also thank the Research Center Network for Realization of Regenerative
Medicine for financially supporting our work, as well as the Japan Science
and Technology Agency (JST) and the Japan Agency for Medical Research
and Development (AMED).
Availability of data and materials
The datasets supporting the conclusions of this article are available in the
following repositories; microarray expression data and CNV data in GEO
[http://www.ncbi.nlm.nih.gov/geo/] (accession numbers: GSE77994 and
GSE77995, respectively); flow cytometry data in FlowRepository [https://
flowrepository.org] (repository ID: FR-FCM-ZZPC).
Also, the precise histological data of this this article is accessible in SKIP
[https://www.skip.med.keio.ac.jp/iPSC-NSPC/]. Our last access date to the
website was 16 Sept 2016.
Authors’ contributions
Conceptualization, KS, RF, and TS; methodology, KS, RF, YK, MN, and HO;
investigation, KS, RF, TS, HF, SK, YN, YH, KK, MI, DK, THT, HS, and EI; writing
the original draft, KS, RF, and TS; writing, review and editing, KS, RF, TS, JK, AI,
YK, MN, and HO; funding acquisition, MN, YK, and OH; project administration,
TM, KK, YK, MN, and HO; supervision, MM, MN, and HO. All authors read and
approved the final manuscript.
Competing interests
H.O. is a paid scientific consultant for San Bio, Co., Ltd. Also, M.I. is employed
by Sumitomo Dainippon Pharma Co., Ltd. All other authors declare that they
have no competing financial interests.
Consent for publication
Not applicable.
Ethics approval and consent to participate
This study was conducted in accordance with the principles of the Helsinki
Declaration. The use of human iPSCs and fetal derived NSPCs was approved
by ethics committees at Keio University School of Medicine (admission
numbers; 20130146, and 20030092, respectively) and Osaka National
Hospital (admission numbers; 110, and 146, respectively).
Author details
1Department of Orthopaedic Surgery, Keio University School of Medicine,
Shinjuku, Tokyo 160-8582, Japan. 2Department of Physiology, Keio University
School of Medicine, 35 Shinanomachi, Shinjuku, Tokyo 160-8582, Japan.
3Department of Pathology, Tokyo Metropolitan Children’s Medical Center,
Fuchu, Tokyo 183-8561, Japan. 4Division of Stem Cell Research, Institute for
Clinical Research, Osaka National Hospital, National Hospital Organization,
Chuo-ku, Osaka 540-0006, Japan. 5Division of Regenerative Medicine, Institute
for Clinical Research, Osaka National Hospital, National Hospital Organization,
Chuo-ku, Osaka 540-0006, Japan. 6Central Institute for Experimental Animals,
Kawasaki, Kanagawa 210-0821, Japan. 7Regenerative & Cellular Medicine
Office, Sumitomo Dainippon Pharma Co., Ltd., Kobe, Hyogo 650-0047, Japan.
8Department of Genetics, Hyogo College of Medicine, Nishinomiya, Hyogo
663-8501, Japan. 9Department of Pathology, Yamaguchi University Graduate
School of Medicine, Ube, Yamaguchi 755-8505, Japan. 10Department of
Neurosurgery, Osaka National Hospital, National Hospital Organization,
Chuo-ku, Osaka 540-0006, Japan.
Received: 27 July 2016 Accepted: 13 September 2016
References
1. Cummings BJ, Uchida N, Tamaki SJ, Salazar DL, Hooshmand M, Summers R,
Gage FH, Anderson AJ. Human neural stem cells differentiate and promote
locomotor recovery in spinal cord-injured mice. Proc Natl Acad Sci U S A.
2005;102(39):14069–74.
2. Iwanami A, Kaneko S, Nakamura M, Kanemura Y, Mori H, Kobayashi S, Yamasaki
M, Momoshima S, Ishii H, Ando K, et al. Transplantation of human neural stem
cells for spinal cord injury in primates. J Neurosci Res. 2005;80(2):182–90.
3. Ishibashi S, Sakaguchi M, Kuroiwa T, Yamasaki M, Kanemura Y, Shizuko I,
Shimazaki T, Onodera M, Okano H, Mizusawa H. Human neural stem/progenitor
cells, expanded in long-term neurosphere culture, promote functional recovery
after focal ischemia in Mongolian gerbils. J Neurosci Res. 2004;78(2):215–23.
4. Kelly S, Bliss TM, Shah AK, Sun GH, Ma M, Foo WC, Masel J, Yenari MA,
Weissman IL, Uchida N, et al. Transplanted human fetal neural stem cells
survive, migrate, and differentiate in ischemic rat cerebral cortex. Proc Natl
Acad Sci U S A. 2004;101(32):11839–44.
5. Kasahara Y, Ihara M, Taguchi A. Experimental evidence and early translational
steps using bone marrow derived stem cells after human stroke. Front Neurol
Neurosci. 2013;32:69–75.
6. Amemori T, Jendelova P, Ruzicka J, Urdzikova LM, Sykova E. Alzheimer’s disease:
mechanism and approach to cell therapy. Int J Mol Sci. 2015;16(11):26417–51.
7. Klein SM, Behrstock S, McHugh J, Hoffmann K, Wallace K, Suzuki M, Aebischer
P, Svendsen CN. GDNF delivery using human neural progenitor cells in a rat
model of ALS. Hum Gene Ther. 2005;16(4):509–21.
8. Svendsen CN, Caldwell MA, Shen J, ter Borg MG, Rosser AE, Tyers P, Karmiol S,
Dunnett SB. Long-term survival of human central nervous system progenitor
cells transplanted into a rat model of Parkinson’s disease. Exp Neurol. 1997;
148(1):135–46.
9. Okano H, Yamanaka S. iPS cell technologies: significance and applications to
CNS regeneration and disease. Mol Brain. 2014;7:22.
10. Turner M, Leslie S, Martin NG, Peschanski M, Rao M, Taylor CJ, Trounson A,
Turner D, Yamanaka S, Wilmut I. Toward the development of a global
induced pluripotent stem cell library. Cell Stem Cell. 2013;13(4):382–4.
11. FDA: Guidance for Industry. Considerations for the Design of Early-Phase
Clinical Trials of Cellular and Gene Therapy Products. 2015.
12. Zhang YM, Hartzell C, Narlow M, Dudley Jr SC. Stem cell-derived cardiomyocytes
demonstrate arrhythmic potential. Circulation. 2002;106(10):1294–9.
13. Lee DR, Yoo JE, Lee JS, Park S, Lee J, Park CY, Ji E, Kim HS, Hwang DY, Kim
DS, et al. PSA-NCAM-negative neural crest cells emerging during neural
induction of pluripotent stem cells cause mesodermal tumors and unwanted
grafts. Stem Cell Reports. 2015;4(5):821–34.
14. Nori S, Okada Y, Nishimura S, Sasaki T, Itakura G, Kobayashi Y, Renault-Mihara F,
Shimizu A, Koya I, Yoshida R, et al. Long-term safety issues of iPSC-based cell
therapy in a spinal cord injury model: oncogenic transformation with
epithelial-mesenchymal transition. Stem Cell Reports. 2015;4(3):360–73.
15. Amariglio N, Hirshberg A, Scheithauer BW, Cohen Y, Loewenthal R, Trakhtenbrot
L, Paz N, Koren-Michowitz M, Waldman D, Leider-Trejo L, et al. Donor-derived
brain tumor following neural stem cell transplantation in an ataxia telangiectasia
patient. PLoS Med. 2009;6(2):e1000029.
Sugai et al. Molecular Brain  (2016) 9:85 Page 14 of 15
16. Gu E, Chen WY, Gu J, Burridge P, Wu JC. Molecular imaging of stem cells:
tracking survival, biodistribution, tumorigenicity, and immunogenicity.
Theranostics. 2012;2(4):335–45.
17. Ito M, Hiramatsu H, Kobayashi K, Suzue K, Kawahata M, Hioki K, Ueyama Y,
Koyanagi Y, Sugamura K, Tsuji K, et al. NOD/SCID/gamma(c)(null) mouse:
an excellent recipient mouse model for engraftment of human cells. Blood.
2002;100(9):3175–82.
18. Greiner DL, Shultz LD, Yates J, Appel MC, Perdrizet G, Hesselton RM, Schweitzer
I, Beamer WG, Shultz KL, Pelsue SC, et al. Improved engraftment of human
spleen cells in NOD/LtSz-scid/scid mice as compared with C.B-17-scid/scid
mice. Am J Pathol. 1995;146(4):888–902.
19. Soncin F, Ward CM. The function of e-cadherin in stem cell pluripotency
and self-renewal. Genes (Basel). 2011;2(1):229–59.
20. Falk A, Koch P, Kesavan J, Takashima Y, Ladewig J, Alexander M, Wiskow O,
Tailor J, Trotter M, Pollard S, et al. Capture of neuroepithelial-like stem cells
from pluripotent stem cells provides a versatile system for in vitro production
of human neurons. PLoS One. 2012;7(1):e29597.
21. Zhang SC, Wernig M, Duncan ID, Brustle O, Thomson JA. In vitro differentiation
of transplantable neural precursors from human embryonic stem cells. Nat
Biotechnol. 2001;19(12):1129–33.
22. Salazar DL, Uchida N, Hamers FP, Cummings BJ, Anderson AJ. Human neural
stem cells differentiate and promote locomotor recovery in an early chronic
spinal cord injury NOD-scid mouse model. PLoS One. 2010;5(8):e12272.
23. Kanemura Y, Mori H, Kobayashi S, Islam O, Kodama E, Yamamoto A, Nakanishi Y,
Arita N, Yamasaki M, Okano H, et al. Evaluation of in vitro proliferative activity of
human fetal neural stem/progenitor cells using indirect measurements of viable
cells based on cellular metabolic activity. J Neurosci Res. 2002;69(6):869–79.
24. Tailor J, Kittappa R, Leto K, Gates M, Borel M, Paulsen O, Spitzer S, Karadottir
RT, Rossi F, Falk A, et al. Stem cells expanded from the human embryonic
hindbrain stably retain regional specification and high neurogenic potency.
J Neurosci. 2013;33(30):12407–22.
25. Isoda M, Kohyama J, Iwanami A, Sanosaka T, Sugai K, Yamaguchi R, Matsumoto T,
Nakamura M, Okano H. Robust production of human neural cells by establishing
neuroepithelial-like stem cells from peripheral blood mononuclear cell-derived
feeder-free iPSCs under xeno-free conditions. Neurosci Res. 2016;110:18–28.
26. Tateno H, Onuma Y, Ito Y, Minoshima F, Saito S, Shimizu M, Aiki Y, Asashima M,
Hirabayashi J. Elimination of tumorigenic human pluripotent stem cells by a
recombinant lectin-toxin fusion protein. Stem Cell Reports. 2015;4(5):811–20.
27. Bulic-Jakus F, Katusic Bojanac A, Juric-Lekic G, Vlahovic M, Sincic N. Teratoma:
from spontaneous tumors to the pluripotency/malignancy assay. Wiley
Interdiscip Rev Dev Biol. 2016;5(2):186–209.
28. Kustikova O, Fehse B, Modlich U, Yang M, Dullmann J, Kamino K, von
Neuhoff N, Schlegelberger B, Li Z, Baum C. Clonal dominance of
hematopoietic stem cells triggered by retroviral gene marking. Science.
2005;308(5725):1171–4.
29. Steinemann D, Gohring G, Schlegelberger B. Genetic instability of modified
stem cells - a first step towards malignant transformation? Am J Stem Cells.
2013;2(1):39–51.
30. Okano H, Nakamura M, Yoshida K, Okada Y, Tsuji O, Nori S, Ikeda E, Yamanaka
S, Miura K. Steps toward safe cell therapy using induced pluripotent stem cells.
Circ Res. 2013;112(3):523–33.
31. Miura K, Okada Y, Aoi T, Okada A, Takahashi K, Okita K, Nakagawa M,
Koyanagi M, Tanabe K, Ohnuki M, et al. Variation in the safety of induced
pluripotent stem cell lines. Nat Biotechnol. 2009;27(8):743–5.
32. Lund RJ, Narva E, Lahesmaa R. Genetic and epigenetic stability of human
pluripotent stem cells. Nat Rev Genet. 2012;13(10):732–44.
33. Nakagawa M, Taniguchi Y, Senda S, Takizawa N, Ichisaka T, Asano K, Morizane
A, Doi D, Takahashi J, Nishizawa M, et al. A novel efficient feeder-free culture
system for the derivation of human induced pluripotent stem cells. Sci Rep.
2014;4:3594.
34. Nishino K, Toyoda M, Yamazaki-Inoue M, Fukawatase Y, Chikazawa E, Sakaguchi
H, Akutsu H, Umezawa A. DNA methylation dynamics in human induced
pluripotent stem cells over time. PLoS Genet. 2011;7(5), e1002085.
35. Gore A, Li Z, Fung HL, Young JE, Agarwal S, Antosiewicz-Bourget J, Canto I,
Giorgetti A, Israel MA, Kiskinis E, et al. Somatic coding mutations in human
induced pluripotent stem cells. Nature. 2011;471(7336):63–7.
36. Hussein SM, Batada NN, Vuoristo S, Ching RW, Autio R, Narva E, Ng S, Sourour
M, Hamalainen R, Olsson C, et al. Copy number variation and selection during
reprogramming to pluripotency. Nature. 2011;471(7336):58–62.
37. Tyson JA, Anderson SA. GABAergic interneuron transplants to study
development and treat disease. Trends Neurosci. 2014;37(3):169–77.
38. Sontag CJ, Uchida N, Cummings BJ, Anderson AJ. Injury to the spinal cord
niche alters the engraftment dynamics of human neural stem cells. Stem
Cell Reports. 2014;2(5):620–32.
39. Piltti KM, Avakian SN, Funes GM, Hu A, Uchida N, Anderson AJ, Cummings
BJ. Transplantation dose alters the dynamics of human neural stem cell
engraftment, proliferation and migration after spinal cord injury. Stem Cell
Res. 2015;15(2):341–53.
40. Temple S. The development of neural stem cells. Nature. 2001;414(6859):
112–7.
41. Okano H, Temple S. Cell types to order: temporal specification of CNS stem
cells. Curr Opin Neurobiol. 2009;19(2):112–9.
42. Yamashita T, Kawai H, Tian F, Ohta Y, Abe K. Tumorigenic development of
induced pluripotent stem cells in ischemic mouse brain. Cell Transplant.
2011;20(6):883–91.
43. Bolande RP. Models and concepts derived from human teratogenesis and
oncogenesis in early life. J Histochem Cytochem. 1984;32(8):878–84.
44. Ishii A, Kimura T, Sadahiro H, Kawano H, Takubo K, Suzuki M, Ikeda E. Histological
characterization of the tumorigenic “Peri-Necrotic Niche” harboring quiescent
stem-like tumor cells in glioblastoma. PLoS One. 2016;11(1):e0147366.
45. Beckwith JB, Kiviat NB, Bonadio JF. Nephrogenic rests, nephroblastomatosis,
and the pathogenesis of Wilms’ tumor. Pediatr Pathol. 1990;10(1–2):1–36.
46. Beckwith JB. Nephrogenic rests and the pathogenesis of Wilms tumor:
developmental and clinical considerations. Am J Med Genet. 1998;79(4):
268–73.
47. Acquarone M, de Melo TM, Meireles F, Brito-Moreira J, Oliveira G,
Ferreira ST, Castro NG, Tovar-Moll F, Houzel JC, Rehen SK. Mitomycin-
treated undifferentiated embryonic stem cells as a safe and effective
therapeutic strategy in a mouse model of Parkinson’s disease. Front Cell
Neurosci. 2015;9:97.
48. Ogura A, Morizane A, Nakajima Y, Miyamoto S, Takahashi J. Gamma-secretase
inhibitors prevent overgrowth of transplanted neural progenitors derived from
human-induced pluripotent stem cells. Stem Cells Dev. 2013;22(3):374–82.
49. Cao F, Drukker M, Lin S, Sheikh AY, Xie X, Li Z, Connolly AJ, Weissman IL,
Wu JC. Molecular imaging of embryonic stem cell misbehavior and suicide
gene ablation. Cloning Stem Cells. 2007;9(1):107–17.
50. Krishnamurthy S, Dong Z, Vodopyanov D, Imai A, Helman JI, Prince ME,
Wicha MS, Nor JE. Endothelial cell-initiated signaling promotes the survival
and self-renewal of cancer stem cells. Cancer Res. 2010;70(23):9969–78.
51. Okita K, Yamakawa T, Matsumura Y, Sato Y, Amano N, Watanabe A, Goshima
N, Yamanaka S. An efficient nonviral method to generate integration-free
human-induced pluripotent stem cells from cord blood and peripheral
blood cells. Stem Cells. 2013;31(3):458–66.
52. Kim DS, Lee JS, Leem JW, Huh YJ, Kim JY, Kim HS, Park IH, Daley GQ, Hwang
DY, Kim DW. Robust enhancement of neural differentiation from human ES
and iPS cells regardless of their innate difference in differentiation propensity.
Stem Cell Rev. 2010;6(2):270–81.
53. Morizane A, Doi D, Takahashi J. Neural induction with a dopaminergic
phenotype from human pluripotent stem cells through a feeder-free
floating aggregation culture. Methods Mol Biol. 2013;1018:11–9.
54. Shofuda T, Fukusumi H, Kanematsu D, Yamamoto A, Yamasaki M, Arita N,
Kanemura Y. A method for efficiently generating neurospheres from
human-induced pluripotent stem cells using microsphere arrays. Neuroreport.
2013;24(2):84–90.
55. Lisa G, Shaffer JM-J, M Schmid. ISCN 2013: An International System for Human
Cytogenetic Nomenclature: Recommendations of the International Standing
Committee on Human Cytogenetic Nomenclature: Karger; 2013.
56. Basso DM, Fisher LC, Anderson AJ, Jakeman LB, McTigue DM, Popovich PG.
Basso Mouse Scale for locomotion detects differences in recovery after spinal
cord injury in five common mouse strains. J Neurotrauma. 2006;23(5):635–59.
Sugai et al. Molecular Brain  (2016) 9:85 Page 15 of 15
